Revumenib
SNDX-5613-0702
Phase 1 small_molecule completed
Quick answer
Revumenib for Relapsed/Refractory Leukemias is a Phase 1 program (small_molecule) at Syndax Pharmaceuticals Inc with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Syndax Pharmaceuticals Inc
- Indication
- Relapsed/Refractory Leukemias
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed